ATHE
Price
$5.00
Change
+$0.39 (+8.46%)
Updated
Jul 18 closing price
Capitalization
80.88M
GLMD
Price
$1.83
Change
-$0.36 (-16.44%)
Updated
Jul 18 closing price
Capitalization
4.13M
10 days until earnings call
Interact to see
Advertisement

ATHE vs GLMD

Header iconATHE vs GLMD Comparison
Open Charts ATHE vs GLMDBanner chart's image
Alterity Therapeutics
Price$5.00
Change+$0.39 (+8.46%)
Volume$302.95K
Capitalization80.88M
Galmed Pharmaceuticals
Price$1.83
Change-$0.36 (-16.44%)
Volume$1.15M
Capitalization4.13M
ATHE vs GLMD Comparison Chart in %
Loading...
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHE vs. GLMD commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a Hold and GLMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (ATHE: $5.00 vs. GLMD: $1.83)
Brand notoriety: ATHE and GLMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHE: 641% vs. GLMD: 342%
Market capitalization -- ATHE: $80.88M vs. GLMD: $4.13M
ATHE [@Biotechnology] is valued at $80.88M. GLMD’s [@Biotechnology] market capitalization is $4.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHE’s FA Score shows that 0 FA rating(s) are green whileGLMD’s FA Score has 0 green FA rating(s).

  • ATHE’s FA Score: 0 green, 5 red.
  • GLMD’s FA Score: 0 green, 5 red.
According to our system of comparison, GLMD is a better buy in the long-term than ATHE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHE’s TA Score shows that 7 TA indicator(s) are bullish while GLMD’s TA Score has 3 bullish TA indicator(s).

  • ATHE’s TA Score: 7 bullish, 2 bearish.
  • GLMD’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ATHE is a better buy in the short-term than GLMD.

Price Growth

ATHE (@Biotechnology) experienced а +8.93% price change this week, while GLMD (@Biotechnology) price change was -5.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

GLMD is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATHE($80.9M) has a higher market cap than GLMD($4.13M). ATHE YTD gains are higher at: 51.057 vs. GLMD (-42.633). GLMD has higher annual earnings (EBITDA): -6.07M vs. ATHE (-19.88M). GLMD has more cash in the bank: 15.7M vs. ATHE (4.54M). GLMD has less debt than ATHE: GLMD (41K) vs ATHE (106K). ATHE (0) and GLMD (0) have equivalent revenues.
ATHEGLMDATHE / GLMD
Capitalization80.9M4.13M1,958%
EBITDA-19.88M-6.07M328%
Gain YTD51.057-42.633-120%
P/E RatioN/A0.02-
Revenue00-
Total Cash4.54M15.7M29%
Total Debt106K41K259%
FUNDAMENTALS RATINGS
ATHE vs GLMD: Fundamental Ratings
ATHE
GLMD
OUTLOOK RATING
1..100
5028
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3761
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
19n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLMD's Valuation (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATHE (89) in the Biotechnology industry. This means that GLMD’s stock grew somewhat faster than ATHE’s over the last 12 months.

GLMD's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ATHE (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to ATHE’s over the last 12 months.

GLMD's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as ATHE (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to ATHE’s over the last 12 months.

ATHE's Price Growth Rating (37) in the Biotechnology industry is in the same range as GLMD (61) in the Pharmaceuticals Other industry. This means that ATHE’s stock grew similarly to GLMD’s over the last 12 months.

GLMD's P/E Growth Rating (96) in the Pharmaceuticals Other industry is in the same range as ATHE (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to ATHE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATHEGLMD
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
72%
Bearish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
71%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 8 days ago
72%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ATHE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALPIB27.60N/A
N/A
Alpine Banks of Colorado
KIKOF8.83N/A
N/A
Kikkoman Corp.
TAPP0.70N/A
N/A
Tap Resources, Inc.
NMKCP65.25N/A
N/A
Niagara Mohawk Power Corp.
EIFZF47.74-0.45
-0.93%
Exchange Income Corp.

ATHE and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHE has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHE
1D Price
Change %
ATHE100%
+8.46%
EYPT - ATHE
54%
Loosely correlated
N/A
TECX - ATHE
37%
Loosely correlated
-5.88%
GLMD - ATHE
31%
Poorly correlated
-21.46%
CVM - ATHE
30%
Poorly correlated
-5.04%
MSCLF - ATHE
28%
Poorly correlated
+0.64%
More

GLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLMD has been loosely correlated with HXBM. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GLMD jumps, then HXBM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLMD
1D Price
Change %
GLMD100%
-21.46%
HXBM - GLMD
38%
Loosely correlated
-20.89%
IOBT - GLMD
33%
Loosely correlated
+2.50%
REVB - GLMD
31%
Poorly correlated
+3.87%
ATHE - GLMD
30%
Poorly correlated
+8.46%
RARE - GLMD
30%
Poorly correlated
-4.01%
More